A novel computational technology that enables the prediction of the
3D structure of G-Protein Coupled Receptors, one of the most
important drug target groups; in-silico targeted screening technology
for the rapid screening of millions of molecules; and use of a 3D
model structure approach to speed up drug optimization.
--Dr. Oren Becker, Predix Pharmaceuticals, Israel
The discovery of two novel prostate-specific proteins encoded by
alternative mRNA splice variants of the genes for prostate specific
antigen (PSA) and its related protein, human kallikrein 2 (hK2). The
novel transcripts were predicted using Compugen's proprietary LEADS
computational biology platform and then verified in Compugen's
molecular biology laboratory
--Dr. Mor Amitai, Compugen Ltd., Israel
How AstraZeneca integrates high speed technologies and large genomic
drug discovery programs, combinatorial and computational chemical
platforms in identification of chemical leads, and integrative
pharmacology for selection of therapeutic concepts.
--Dr. M. Dohlsten, AstraZeneca, Sweden
A breakthrough in schizophrenia drug research. For the first time
certain genes have been identified as schizophrenia risk factors.
This breakthrough is based on a technology for identifying disease
risk factors in a general population, developed utilizing the high
level of genetic homogeneity among the Ashkenazi Jewish population.
--Dr. Ariel Darvasi, IDgene Pharmaceuticals, Israel
Computational tools that show how genes influence other genes via
proteins. This innovative system was developed to detect the
influence on known genomic networks and pathways as a result of the
introduction of certain putative genes.
--Prof. Ron Shamir, Tel Aviv University
New structural bioinformatics tools for in-silico target detection
and drug screening, in particular algorithms for detection of novel
structural and functional motifs, protein active sites and prediction
of protein-binding characteristics. These tools speed up drug
discovery by minimizing the number of drug candidates that need to be
tested in the lab and on patients.
--Prof. H. Wolfson, Tel-Aviv University
The Weizmann Institute Genome Center as a model for combining gene
discovery, integrated database development and DNA microarrays. All
three activities revolve around the development of a strong capacity
in computational genomics and bioinformatics.
--Prof. D. Lancet, Weizmann Institute of Science